We advised GH Research on the establishment of the at-the-market program

Davis Polk advised GH Research PLC in connection with the establishment of its SEC-registered at-the-market offering of ordinary shares for up to an aggregate amount of $200 million. The ordinary shares are listed on the Nasdaq Global Market under the ticker symbol “GHRS.”

GH Research is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. The company’s initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression.

The Davis Polk corporate team included partners Deanna L. Kirkpatrick and Yasin Keshvargar, counsel Steven Glendon and associate Robert Van de Mark. Partner David R. Bauer and associates Shreya R. Kundur and Anne Kim provided intellectual property advice. Special counsel Mario J. Verdolini and associates Shea Jendrusina and Afrika Nora Owes provided tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post